Kenneth H. Shain, MD, PhD

Articles

Dr Shain on the Evolving Role of Bispecific Antibodies in Multiple Myeloma Management

October 31st 2024

Kenneth Shain, MD, PhD, discusses the evolving role of bispecific antibodies in the management of multiple myeloma.

Management of Patients with RRMM

November 12th 2021

Kenneth Shain, MD, PhD discusses multiple myeloma disease measurement, management, and personalization of treatment going forward.

Emerging Therapies in RRMM

November 12th 2021

Dr Kenneth Shain, a multiple myeloma expert, discusses emerging therapies with newer mechanisms of action for patients with RRMM.

PORT Trial

November 12th 2021

Multiple myeloma expert Dr Kenneth Shain discusses the PORT study comparing central vs peripheral administration of melphalan flufenamide.

OCEAN Trial

November 12th 2021

Kenneth Shain, MD, PhD reviews phase 3 OCEAN study design and safety and efficacy data from patients with RRMM treated with melphalan flufenamide + dexamethasone doublet or pomalidomide + dexamethasone.

Melphalan flufenamide

November 12th 2021

Multiple myeloma expert Dr Kenneth Shain discusses mechanism of action of melphalan flufenamide and the advantage it might offer to fight cancer cells.

Relapsed/Refractory Multiple Myeloma Landscape

November 12th 2021

Kenneth Shain, MD, PhD provides an overview of recent advances in the treatment of relapsed and refractory multiple myeloma.

Dr. Shain Discusses the Role of Stem Cell Transplant in Myeloma

September 12th 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.

Dr. Shain Discusses Novel Agents in Multiple Myeloma

August 31st 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.

Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

August 9th 2017

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

Dr. Shain Discusses Emerging Agents in Multiple Myeloma

May 26th 2017

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.